The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study
Satoru Taguchi(Iwate Medical University), Haruki Kume, Taketo Kawai(National Center for Global Health and Medicine), Jun Kamei(The University of Tokyo), Kazuki Maki(The University of Tokyo), Tappei Takada(University of Tokyo Hospital), Naoki Saegusa(The University of Tokyo), Yoshiaki Kurokawa(The University of Tokyo), Katsuhiko Nara(University of Tokyo Hospital), Tomoyuki Kaneko(Teikyo University), Daisuke Yamada(St. Luke's International Hospital), Jimpei Miyakawa(Kyorin University), Takehiro Tanaka(Okayama University), Yuumi Tokura(Teikyo University), Yuta Yamada(Yamagata University), Aya Niimi(The University of Tokyo), Tohru Nakagawa(Sapporo Kosei General Hospital), Yoichi Fujii(The University of Tokyo), Y. Ambe(The University of Tokyo), Shigenori Kakutani(The University of Tokyo), Kazuki Honda(The University of Tokyo), Masahiro Yamamoto(Albany State University)
Cited by 3
Related Papers
Decreased extra-renal urate excretion is a common cause of hyperuricemia
|Nature Communications|2012|703
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
|Science Translational Medicine|2009|438
Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes
|Annals of the Rheumatic Diseases|2015|185
A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy
|PLoS ONE|2008|180
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes
|Annals of the Rheumatic Diseases|2016|177